Lili Deng^*1, Xue Yang^†1, Jun Fan^*, Yuedi Ding^*, Ying Peng^*, Dong Xu^*, Biao Huang^*‡, Zhigang Hu^†

Oncology Research, Vol.28, No.6, pp. 579-590, 2020, DOI:10.3727/096504020X15942028641011

Abstract Colorectal cancer is an aggressive malignancy for which there are limited treatment options. Oncolytic vaccinia virus is being developed as a novel strategy for cancer therapy. Arming vaccinia virus with immunostimulatory cytokines can enhance the tumor cell-specific replication and antitumor efficacy. Interleukin-24 (IL-24) is an important immune mediator, as well as a broad-spectrum tumor suppressor. We constructed a targeted vaccinia virus of Guang9 strain harboring IL-24 (VG9-IL-24) to evaluate its antitumor effects. In vitro, VG9-IL-24 induced an increased number of apoptotic cells and blocked colorectal cancer cells in the G₂ /M phase of the cell cycle. More >

Bo Ling, Zuliang Huang, Suoyi Huang, Li Qian, Genliang Li, Qianli Tang

Oncology Research, Vol.28, No.6, pp. 561-578, 2020, DOI:10.3727/096504020X15907428281601

Abstract There is growing evidence on the clinical significance of tumor microenvironment (TME) cells in predicting prognosis and therapeutic effects. However, cell interactions in tumor microenvironments have not been thoroughly studied or systematically analyzed so far. In this study, 22 immune cell components in the lung adenocarcinoma (LUAD) TME were analyzed using gene expression profile from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). The TME-based molecular subtypes of LUAD were defined to evaluate further the relationship between molecular subtypes, prognosis, and clinical characteristics. A TME risk score model was constructed by using the More >

Jacob J. Adashek¹, Alex Leonard^2,*, Samantha W. Nealon³, Arvind Krishnan³, Gerard C. Mosiello⁴, Jasreman Dhillon⁵, Philippe E. Spiess³

Canadian Journal of Urology, Vol.26, No.6, pp. 10012-10021, 2019

Abstract Introduction: Extramammary Paget’s disease (EMPD) is a rare and complex condition, for which no established guidelines exist regarding diagnosis and management. There have been recent improvements in the diagnosis and management of EMPD, largely due to an enhanced understanding of its underlying pathogenesis.
Materials and methods: A literature search on PubMed including articles that describe pathogenesis, clinical diagnosis, treatment modalities, and future treatment were selected and included to build this review.
Results: Recent studies suggest the expression of HER2 and androgen receptors, which could be useful targets for future treatment strategies. Carcinoembryonic antigen as a biomarker for EMPD More >

Longwei Liu¹, Praopim Limsakul¹, Shaoying (Kathy) Lu¹, Peter Yingxiao Wang^1,*

Molecular & Cellular Biomechanics, Vol.16, Suppl.2, pp. 82-82, 2019, DOI:10.32604/mcb.2019.07360

Abstract Genetically-encoded biosensors based on Fluorescence Resonance Energy Transfer (FRET biosensors) have been widely used to dynamically track the activity of Protein Tyrosine Kinases (PTKs) in living cells because of their sensitive ratiometric fluorescence readout, high spatiotemporal resolution. However, the limitation in sensitivity, specificity, and dynamic range of these biosensors have hindered their broader applications, and there was a lack of efficient ways to optimize FRET biosensors. Here we established a rapid, systematic and universal approach for FRET biosensor optimization through directed evolution which involves generating genetic diversity and screening for protein variants with desired properties… More >

Jacqueline Zillioux¹, Matthew DiLizia², Basil Schaheen³, Rudolph Rustin³, Tracey L. Krupski¹

Canadian Journal of Urology, Vol.25, No.5, pp. 9525-9526, 2018

Abstract Atezolizumab is a promising immunotherapy for advanced urothelial carcinoma. Like other immune checkpoint inhibitors, it can produce rare immune-related adverse events (IRAEs). Here we present the recent case of a patient with metastatic bladder cancer who developed diarrhea and abdominal pain months after beginning atezolizumab therapy. He presented to our institution with an ileal perforation secondary to atezolizumabinduced enterocolitis. After surgical repair, the patient’s condition improved, and he was discharged. We discuss the management of atezolizumab-induced enterocolitis, including the importance of early recognition and intervention to prevent more devastating complications. More >

Alvaro Morales

Canadian Journal of Urology, Vol.24, No.3, pp. 8788-8793, 2017

Abstract Introduction: It is 40 years since the initial documentation of the efficacy of bacille Calmette-Guérin (BCG) in the management of non-muscle invasive bladder cancer (NMIBC) and probably an opportune a time as any to retrace the origins of this development and to reflect on the progress that has occurred on the use of immune modifiers in the treatment of NMIBC.
Materials and methods: A PubMed search for publications on the history of BCG was conducted, and those related to the development of the vaccine for protection against tuberculosis as well as those published in the last 40… More >

Jian-lin Yang^*1, Ye Qin^*1, Liang Li^†, Chu-yu Cao^*, Qing Wang^*, Qian Li^*, Ya-feng Lv^*, Yanlin Wang^*

Oncology Research, Vol.23, No.1-2, pp. 79-86, 2015, DOI:10.3727/096504015X14478843952942

Abstract In the process of tumor cell apoptosis induced by specific regents, calreticulin (CRT) was transferred from endoplasmic reticulum (ER) onto the cell membrane. These tumor cells, when used as the cellular vaccine to immunize experimental animals, could initiate effective antitumor immunoresponse against homologous tumor cells. This is referred to as immunogenic cell death. Lidamycin (LDM) is an enediyne antibiotic, which has extremely potent cytotoxicity to cancer cells. In this study, the mouse melanoma B16-F1 cancer cells were used to investigate the ability of LDM in promoting immunogenic cell death. Our data showed that LDM could… More >

Leonard G. Gomella, Francisco Gelpi-Hammerschmidt, Chandan Kundavram

Canadian Journal of Urology, Vol.21, Suppl.2, pp. 48-56, 2014

Abstract instruction: Introduction: New treatment options for metastatic castration-resistant prostate cancer (mCRPC) have become available over the last few years should primary treatments and androgen deprivation therapies fail. While historically not considered to be amenable to immunotherapy, the treatment of advanced prostate cancer using this approach is an area of intense interest and now clinical application.
instruction: Materials and methods: Recent literature on castration-resistant prostate cancer management with a focus on immunotherapeutic strategies was reviewed. Mechanisms of action involving the immunologic treatment of cancer were identified. Agents in clinical trials with near-term application in prostate cancer were also… More >

Prashant Malhotra, Bruce F. Farber

Canadian Journal of Urology, Vol.18, No.3, pp. 5671-5675, 2011

Abstract Bacillus Calmette Guerin (BCG) immunotherapy is widely used for treatment of superfi cial bladder transitional cell carcinoma. Infectious complications while rare can be serious and severe disseminated infections as well as sepsis has been reported. There are no standard guidelines to direct therapy of these complications. Isoniazid is a commonly and widely used component of the various treatment regimens. Various strains of BCG are used for treatment of bladder cancer as well as vaccinations. These strains have evolved because of repeated subcultures in various laboratories in the world and have been shown to exhibit phenotypic… More >

Bob Djavan

Canadian Journal of Urology, Vol.18, No.4, pp. 5763-5763, 2011

Abstract This article has no abstract. More >